LB PHARMACEUTICALS INC

8-K · d138757d8k.htm

0001691082 2026-06-03 2026-06-03
  
  
 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
  
  

 FORM 8-K
  
  

 CURRENT REPORT
 Pursuant to Section 13 or 15(d)
 of the Securities Exchange Act of 1934
 Date of Report (Date of earliest event reported): June 3, 2026
  
  

 LB Pharmaceuticals Inc
 (Exact name of registrant as specified in its charter)
  
  

  

 Delaware
  
 001-42831
  
 81-1854347

 (state or other jurisdiction
 of incorporation)

  
 (Commission
 File Number)

  
 (I.R.S. Employer
 Identification No.)

  

 One Pennsylvania Plaza , Suite 1025
 New York , NY

  
 10119

 (Address of principal executive offices)
  
 (Zip Code)

 Registrant’s telephone number, including area code: (212) 605-0300
 Not applicable
 (Former name or former address, if changed since last report.)
  
  

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
  

 ☐
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  

 ☐
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  

 ☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

 ☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:
  

 Title of each class

  
 Trading
 Symbol

  
 Name of each exchange
 on which registered

 Common Stock, $0.0001 par value per share
  
 LBRX
  
 The Nasdaq Stock Market LLC

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 Emerging growth company ☒
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
  
  
  

 Item 5.07. Submission of Matters to a Vote of Security Holders.
 LB Pharmaceuticals Inc (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 3, 2026, at which a quorum was present. The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. These proposals are described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 23, 2026.
 Proposal 1 – Election of Directors
 The Company’s stockholders elected the three persons listed below as Class I directors, each to serve a three-year term until the Company’s 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results were as follows:
  

  
   
 For
   
 Withheld
   
 Broker Non-Votes

 Robert A. Lenz, M.D., Ph.D.

   
 20,059,577
   
     8,004
   
 3,216,636

 Rebecca Luse

   
 18,530,680
   
 1,536,901
   
 3,216,636

 Ran Nussbaum

   
 18,748,511
   
 1,319,070
   
 3,216,636

 Proposal 2 – Ratification of the Appointment of Independent Registered Public Accounting Firm
 The Company’s stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results were as follows:
  

 For
  
 Against
  
 Abstain
  
 Broker Non-Votes

 23,275,974

  
 5,490

  
 2,753

  
 — 

 SIGNATURES
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  

 LB PHARMACEUTICALS INC

 By:
  
 /s/ Heather Turner

  
 Heather Turner
 Chief Executive Officer

 Dated: June 9, 2026